In a report released yesterday, Marc Wiesenberger from B.Riley FBR reiterated a Buy rating on Zynex (ZYXI), with a price target of $18.50. The company’s shares closed last Tuesday at $11.93.
Wiesenberger has an average return of 83.2% when recommending Zynex.
According to TipRanks.com, Wiesenberger is ranked #990 out of 6281 analysts.
Zynex has an analyst consensus of Strong Buy, with a price target consensus of $16.17, representing a 27.5% upside. In a report issued on April 1, Northland Securities also initiated coverage with a Buy rating on the stock with a $15.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.28 and a one-year low of $4.81. Currently, Zynex has an average volume of 350K.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZYXI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.
